Latest News and Press Releases
Want to stay updated on the latest news?
-
EXTON, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
-
EXTON, Pa., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs,...
-
Patient Dosing in Phase II Trial of azficel-T for Chronic Dysphonia Completed Preclinical Toxicology Study for FCX-007 InitiatedPositive POC Data Shows FCX-013 Reduces Dermal Thickness of...
-
EXTON, Pa. and GERMANTOWN, Md., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company translating personalized biologics into...
-
- Company to Host Conference Call and Webcast, Today at 8:30 a.m. EST - EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy...
-
EXTON, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and...
-
EXTON, Pa. and GERMANTOWN, Md., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments...
-
EXTON, Pa., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and...
-
EXTON, Pa. and GERMANTOWN, Md., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments...
-
EXTON, Pa., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious...